

May 28, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir,

Sub: Outcome of the Board Meeting held on May 28, 2019.

The Board of Directors of the Company at its meeting held today, May 28, 2019, has inter alia, transacted the following businesses:

1. Approved the standalone and consolidated Audited Financial Results of the Company for the fourth Quarter and year ended March 31, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2019 with unmodified opinion.
2. Approved the Scheme of Amalgamation ("Scheme") pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz., APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ("Transferor Companies") with Aurobindo Pharma Limited ("Transferee Company"). The Scheme would be subject to requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). A separate disclosure is being made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the members in the forthcoming Annual General Meeting, has approved the:
 - (a) re-appointment of Mrs. Savita Mahajan as Independent Director of the Company for a second term of 5 consecutive years from December 16, 2019 to December 15, 2024. She is not related to any other Directors of the Company and does not hold any shares in the Company,
 - (b) re-appointment of Dr.(Mrs). Avnit Bimal Singh as Independent Director of the Company for a second term of 5 consecutive years from March 25, 2020 to March 24, 2025. She is not related to any other Directors of the Company and does not hold any shares in the Company and
 - (c) re-appointment of Mr. P.Sarath Chandra Reddy as Wholetime Director of the Company for a period of 3 years with effect from June 1, 2019. He is related to Mr.P.V.Ramprasad Reddy and Mr.K.Nithyananda Reddy, Directors of the Company.

(CIN : L24239TG1986PLCO15190)

AUROBINDO PHARMA LIMITED

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No. V1, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. off.: Plot No. 2, Muthivivar, Ammalpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

We hereby affirm that Mrs. Savita Mahajan, Dr.(Mrs). Avnit Bimal Singh and Mr.P.Sarath Chandra Reddy are not debarred from holding the office of Director by virtue of any SEBI order or any such authority. A brief profile of Mrs. Savita Mahajan, Dr.(Mrs). Avnit Bimal Singh and Mr.P.Sarath Chandra Reddy are enclosed as **Annexure -1**.

We also enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth Quarter and year ended March 31, 2019.

The Board meeting commenced at 4.00 p.m. and concluded at 7.25 p.m.

Yours faithfully,

For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary

Enclosures: as above.



AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maltrivihar, Amaerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aubindindo.com

(Rs. in lakhs)

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2019

Particulars	Quarter ended			Year ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from operations					
(a) Net sales/ income from operations (refer note 3)	319,620	316,050	229,632	1,193,870	1,004,196
(b) Other operating Income	8,438	8,760	5,840	31,919	26,119
Total revenue from operations	328,058	324,810	235,472	1,225,789	1,030,315
2 Other Income					
(a) Foreign exchange gain (net)	1,078	5,180	295	-	5,853
(b) Others	1,753	8,507	341	10,960	2,212
Total other Income	2,831	13,687	636	10,960	8,065
Total Income (1+2)	330,889	338,497	236,108	1,236,749	1,038,380
3 Expenses					
(a) Cost of materials consumed	170,820	170,414	119,149	645,530	489,327
(b) Purchase of stock-in-trade	58	371	42	1,425	372
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(13,690)	(2,243)	(9,049)	(28,980)	(33,418)
(d) Employee benefits expense	36,182	34,986	31,739	136,277	113,164
(e) Finance costs	3,484	4,141	1,741	13,092	5,289
(f) Foreign exchange loss (net) (refer note 7)	-	-	-	1,032	-
(g) Depreciation and amortisation expense	10,933	10,910	9,155	41,303	35,483
(h) Other expenses	61,254	61,450	45,803	230,608	193,869
Total expenses	269,041	280,029	198,580	1,040,287	804,086
4 Profit before tax (1+2-3)	61,848	58,468	37,528	196,462	234,294
5 Tax expense					
Current tax	13,165	12,878	7,202	42,661	50,534
Tax credit - Minimum Alternate Tax (MAT)	887	(1,828)	(3,450)	(4,805)	(4,332)
Deferred tax	1,782	1,067	2,947	5,633	6,815
Total tax expense	15,834	12,117	6,699	43,489	53,017
6 Net profit for the period/year (4-5)	46,014	46,351	30,829	152,973	181,277
7 Other Comprehensive Income					
Items that will not be reclassified subsequently to profit or loss:					
(a) Re-measurement of defined benefit liability	(69)	(49)	283	(217)	(345)
(b) Income-tax relating to items that will not be reclassified to profit or loss	24	17	(90)	76	127
Total Comprehensive Income for the period/year (6+7)	45,969	46,319	31,022	152,832	181,059
9 Paid-up equity share capital (face value Rs. 1 per share)	5,859	5,859	5,859	5,859	5,859
10 Other equity				1,129,203	992,399
11 Earnings per equity share (face value Rs. 1 per share)	(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)
(a) Basic (in Rs.)	7.85	7.91	5.26	26.11	30.94
(b) Diluted (in Rs.)	7.85	7.91	5.26	26.11	30.94

NOTES:

- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 28 May 2019. The statutory auditors have carried out audit of the above results for the year ended 31 March 2019. An unqualified report has been issued by them thereon.
- Post Implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenues from operations is disclosed net of GST. Revenue from operations for the quarter and year ended 31 March 2019, quarter ended 31 March 2018 and quarter ended 31 December 2018 are reported net of GST. The year ended 31 March 2018 include excise duty upto 30 June 2017.
- Effective 1 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Company.
- The Company operates in only one segment viz., 'Pharmaceutical Products'.
- Sales of standalone include exports of Rs. 270,079 lakhs for the current quarter (31 March 2018: Rs. 188,309 lakhs) and of Rs.999,088 lakhs for the year ended 31 March 2019 (31 March 2018: Rs.832,493 lakhs).
- Foreign exchange loss includes exchange difference of Rs.Nil lakhs for quarter ended 31 March 2019 and Rs. 9,994 lakhs for the year ended 31 March 2019 respectively arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on Borrowing costs.
- During the quarter:
 - Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc. acquired certain identified business (Portfolio of oncology injectable business) from Spectrum Pharmaceuticals Inc. w.e.f. 1 March 2019.
 - The following companies are acquired w.e.f. 8 February 2019:
 - Aurovitas Pharma Polska, a wholly owned subsidiary of Agile Pharma B.V. acquired Apotex Polska S.p. z o.o., Poland
 - Aurovitas Pharma Ceska Republica s.r.o., a wholly owned subsidiary of Agile Pharma B.V. acquired APOTEX (CR) Spol. s.r.o. Czech Republic.
 - Aurovitas Spain S.A. a wholly owned subsidiary of Agile Pharma B.V. acquired APOTEX ESPANA SL, Spain.
 - Aurobindo Pharma B.V. a wholly owned subsidiary of Agile Pharma B.V. acquired Apotex N.V., Belgium, Apotex Europe B.V., The Netherlands and Apotex Nederland B.V., The Netherlands, which has wholly owned step down subsidiaries Sameko Farma B.V, The Netherlands, Leidapharm B.V, The Netherlands, Marel B.V, The Netherlands and Pharma Dossier B.V, The Netherlands.
 - The following Companies are Incorporated :
 - Curateq Biologics GmbH, Switzerland was Incorporated as wholly owned subsidiary of Helix Healthcare B.V, The Netherlands w.e.f. 20 March 2019.
 - Aurobindo Pharma FZ-LLC, Dubai was Incorporated as wholly owned subsidiary of Helix Healthcare B.V, The Netherlands w.e.f. 1 January 2019
 - Auro Science LLC, U.S.A was Incorporated as wholly owned subsidiary of Aurobindo Pharma USA, Inc., w.e.f.28 March 2019.
- The figures of the quarter ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2019 and 31 March 2018 respectively and the unaudited published year to date figures upto 31 December 2018 and 31 December 2017 respectively, being the date of the end of the third quarter of the financial year. The standalone results for the nine months ended 31 December 2018 and 31 December 2017 have been subjected to the limited review by the statutory auditors.
- Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date: 28 May 2019



FOR PURPOSE ONE

Standalone Balance Sheet

(Rs. in lakhs)

Sl. No.	PARTICULARS	As at 31.03.2019	As at 31.03.2018
		(Audited)	(Audited)
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	414,585	339,297
	Capital work-in-progress	75,007	110,023
	Intangible assets	385	-
	Intangible assets under development	3,894	4,375
	Financial assets		
	Investments	233,904	196,748
	Loans	14,656	1,326
	Trade receivables	-	-
	Other financial assets	9,827	9,641
	Non-current tax assets (net)	13,811	8,260
	Other non-current assets	7,169	11,594
	Total non-current assets	773,238	681,264
2	Current assets		
	Inventories	397,126	340,923
	Financial assets		
	Investments	2	2
	Trade receivables	523,207	446,823
	Cash and cash equivalents	7,340	24,400
	Bank balances other than cash and cash equivalents	237	190
	Loans	982	823
	Other financial assets	2,025	814
	Other current assets	109,915	84,145
	Total current assets	1,040,834	898,120
	TOTAL ASSETS	1,814,072	1,579,384
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,859
	Other equity	1,129,203	992,399
	Total equity	1,135,062	998,258
	Liabilities		
2	Non-current liabilities		
	Provisions	2,264	3,360
	Deferred tax liability (net)	3,100	2,348
	Total non-current liabilities	5,364	5,708
3	Current liabilities		
	Financial liabilities		
	Borrowings	451,980	365,383
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises and	3,288	2,966
	total outstanding dues of creditors other than micro enterprises and small enterprises	180,851	159,958
	Other financial liabilities	12,869	25,265
	Other current liabilities	15,007	14,392
	Provisions	9,651	7,454
	Total current liabilities	673,646	575,418
	TOTAL EQUITY AND LIABILITIES	1,814,072	1,579,384



28



IDENTIFICATION PURPOSE ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Independent Auditors' Report on Standalone Annual Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of Aurobindo Pharma Limited

We have audited the accompanying standalone annual financial results of Aurobindo Pharma Limited ('the Company') for the year ended 31 March 2019 (the 'Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that figures for last the quarter ended 31 March 2019 and the corresponding quarter ended in the previous year as reported in these standalone annual financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

These standalone annual financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results upto the end of the third quarter which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these standalone annual financial results based on our audit of the annual financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the standalone annual financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.



Independent Auditors' Report on Standalone Annual Financial Results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view of the net profit and other comprehensive income and other financial information for the year ended 31 March 2019.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration Number: 116231W/W-100024



Sriram Mahalingam

Partner

Membership Number: 049642

Place: Hyderabad

Date: 28 May 2019

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2019

Particulars	Quarter ended			Year ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from operations					
(a) Net sales/ income from operations (refer note 4)	520,198	517,526	398,863	1,922,592	1,623,287
(b) Other operating income	9,022	9,441	6,046	33,763	26,697
Total revenue from operations	529,220	526,967	404,909	1,956,355	1,649,984
2 Other Income					
(a) Foreign exchange gain (net)	-	5,045	-	-	-
(b) Others	3,227	1,340	4,383	11,566	10,198
Total other income	3,227	6,385	4,383	11,566	10,198
Total Income (1+2)	532,447	533,352	409,292	1,967,921	1,660,182
3 Expenses					
(a) Cost of materials consumed	199,129	192,256	142,779	744,499	562,937
(b) Purchase of stock-in-trade	51,222	55,184	46,673	194,320	160,588
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(13,088)	(8,452)	(22,505)	(67,555)	(48,251)
(d) Employee benefits expense	71,346	64,980	58,127	258,487	213,084
(e) Finance costs	5,008	4,765	2,472	16,266	7,771
(f) Foreign exchange loss (net)	284	-	1,592	6,028	1,676
(g) Depreciation and amortisation expense	18,662	16,312	15,663	66,795	55,797
(h) Other expenses	114,580	114,361	99,432	431,410	382,774
Total expenses	447,143	439,406	344,233	1,650,250	1,336,376
4 Profit before share of profit of joint ventures, exceptional item (1+2-3)	85,304	93,946	65,059	317,671	323,806
5 Share of profit/(loss) of joint ventures, net of tax	(52)	257	56	270	314
6 Profit before exceptional items and tax (4+5)	85,252	94,203	65,115	317,941	324,120
7 Exceptional items (refer note 6)	3,618	2,504	-	8,806	-
8 Profit before tax (6-7)	81,634	91,699	65,115	309,135	324,120
9 Tax expense					
Current tax	18,998	21,365	4,222	71,207	71,230
Tax credit - Minimum Alternate Tax (MAT)	1,658	(2,551)	(3,450)	(5,100)	(4,332)
Deferred tax	2,456	1,664	11,467	6,578	14,930
Total tax expense	23,112	20,478	12,239	72,685	81,828
10 Net profit for the period/year after tax and before non-controlling interest (8-9)	58,522	71,221	52,876	236,450	242,292
11 Share of profit/(loss) attributable to non-controlling interest	(16)	(1)	25	(23)	(26)
12 Net profit after taxes attributable to owners of the Parent Company (10-11)	58,538	71,222	52,851	236,473	242,318
13 Other Comprehensive Income/(Loss)					
A) Items that will not be reclassified subsequently to profit or loss:					
i) Re-measurement of defined employee benefit liability	(122)	(49)	283	(261)	(367)
ii) Income-tax relating to items that will not be reclassified to profit or loss	57	14	(87)	107	130
B) Items that will be reclassified subsequently to profit or loss:					
i) Exchange differences on translating the financial statements of foreign operations	(5,637)	(17,309)	10,184	(266)	15,191
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-
Total other comprehensive income/(loss)	(5,702)	(17,344)	10,380	(420)	14,954
14 Total Comprehensive Income for the period/year (12+13)	52,836	53,878	63,231	236,053	257,272
15 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859
16 Other equity				1,383,219	1,162,183
17 Earnings per equity share (face value Re. 1 per share)					
(a) Basic (in Rs.)	9.99	12.15	9.02	40.36	41.36
(b) Diluted (in Rs.)	9.99	12.15	9.02	40.36	41.36

NOTES:

- The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 28 May 2019. The statutory auditors have carried out audit of the above results for year ended 31 March 2019. An unqualified report has been issued by them thereon.
- Post Implementation of Goods and Services Tax ("GST") with effect from 01 July 2017, revenues from operations is disclosed net of GST. Revenue from operations for the quarter and year ended 31 March 2019, quarter ended 31 March 2018 and quarter ended 31 December 2018 are reported net of GST. The year ended 31 March 2018 include excise duty upto 30 June 2017.
- Effective 1 April 2018, the Group has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
- Exceptional items for the current period/year represents acquisition related costs.
- The Group operates in only one segment viz., 'Pharmaceutical Products'.
- During the quarter:
 - Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc. acquired certain identified business (Portfolio of oncology injectable business) from Spectrum Pharmaceuticals Inc. w.e.f. 1 March 2019.
 - The following companies are acquired w.e.f. 8 February 2019:
 - Aurovit Pharma Polska, a wholly owned subsidiary of Agile Pharma B.V. acquired Apotex Polska S.p. z o.o., Poland
 - Aurovit Pharma Ceska Republika s.r.o., a wholly owned subsidiary of Agile Pharma B.V. acquired APOTEX (CR) Spol. s.r.o. Czech Republic.
 - Aurovit Pharma S.A. a wholly owned subsidiary of Agile Pharma B.V. acquired APOTEX ESPANA SL, Spain.
 - Aurobindo Pharma B.V. a wholly owned subsidiary of Agile Pharma B.V. acquired Apotex N.V., Belgium, Apotex Europe B.V., The Netherlands and Apotex Nederland B.V., The Netherlands, which has wholly owned step down subsidiaries Sameko Farma B.V., The Netherlands, Leidapharm B.V., The Netherlands, Marel B.V., The Netherlands and Pharma Dossier B.V., The Netherlands.
 - The following Companies are incorporated:
 - Curateq Biologics GmbH, Switzerland was incorporated as wholly owned subsidiary of Helix Healthcare B.V., The Netherlands w.e.f. 20 March 2019.
 - Aurobindo Pharma FZ-LLC, Dubai was incorporated as wholly owned subsidiary of Helix Healthcare B.V., The Netherlands w.e.f. 1 January 2019
 - Auro Science LLC, U.S.A was incorporated as wholly owned subsidiary of Aurobindo Pharma USA, Inc., w.e.f. 28 March 2019.
- The consolidated financial results for the current quarter and year ended 31 March 2019 include the results of operations of the above entities from their respective dates of acquisition or incorporation. The corresponding figures for the previous periods are not comparable.
- The figures of the quarter ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2019 and 31 March 2018 respectively and the unaudited published year to date figures upto 31 December 2018 and 31 December 2017 respectively, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended 31 December 2018 and 31 December 2017 have been subjected to the limited review by the statutory auditors.
- Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date: 28 May 2019



Consolidated Balance Sheet

(Rs. in lakhs)

Sl. No.	PARTICULARS	As at 31.03.2019	As at 31.03.2018
		(Audited)	(Audited)
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	569,365	473,656
	Capital work-in-progress	134,194	139,954
	Goodwill	83,251	81,654
	Other intangible assets	194,869	96,757
	Intangible assets under development	32,652	18,350
	Financial assets		
	Investments	36,020	31,152
	Loans	646	544
	Trade receivables	119	-
	Other financial assets	8,938	8,684
	Deferred tax assets (net)	18,329	15,880
	Non-current tax assets (net)	13,811	8,259
	Other non-current assets	16,792	17,398
	Total non-current assets	1,108,986	892,288
2	Current assets		
	Inventories	724,560	585,842
	Financial assets		
	Investments	2	2
	Trade receivables	341,378	308,020
	Cash and cash equivalents	188,607	121,590
	Bank balances other than cash and cash equivalents	7,111	4,635
	Loans	1,026	866
	Other financial assets	136,346	79,420
	Current tax assets (net)	3,456	6,455
	Other current assets	133,965	110,987
	Total current assets	1,536,451	1,217,817
	TOTAL ASSETS	2,645,437	2,110,105
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,859
	Other equity	1,383,219	1,162,183
	Non-controlling interest	159	182
	Total equity	1,389,237	1,168,224
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	17,995	45,120
	Provisions	4,654	5,586
	Deferred tax liabilities (net)	28,131	23,528
	Other non-current liabilities	1,130	1,057
	Total non-current liabilities	51,910	75,291
3	Current liabilities		
	Financial liabilities		
	Borrowings	657,321	403,134
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises and	3,361	3,083
	total outstanding dues of creditors other than micro enterprises and small enterprises	264,352	234,207
	Other financial liabilities	166,146	150,452
	Other current liabilities	88,395	46,291
	Provisions	18,088	19,728
	Current tax liabilities (net)	6,627	9,695
	Total current liabilities	1,204,290	866,590
	TOTAL EQUITY AND LIABILITIES	2,645,437	2,110,105



IDENTIFICATION PURPOSE ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Independent Auditors' Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of Aurobindo Pharma Limited

1. We have audited the consolidated annual financial results of Aurobindo Pharma Limited ('the Company') for the year ended 31 March 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the last quarter ended 31 March 2019 and the corresponding quarter ended in the previous year as reported in these consolidated annual financial results are the balancing figures between consolidated audited figures in respect of the full financial year and the published year to date consolidated figures upto the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
2. These consolidated annual financial results have been prepared from consolidated annual financial statements and reviewed quarterly consolidated financial results upto the end of the third quarter which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these consolidated annual financial results based on our audit of such consolidated annual financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.
3. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated annual financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.
4. We did not audit the financial statements of 66 subsidiaries included in the consolidated annual financial results, whose annual financial statements reflect total assets of Rs. 2,062,189 lakhs as at 31 March 2019 as well as the total revenue of Rs. 1,510,230 lakhs for the year ended 31 March 2019. The consolidated annual financial results also include the Group's share of net profit (and other comprehensive income) of Rs. 15 lakhs for the year ended 31 March 2019 in respect of five joint ventures. These annual financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the consolidated annual financial results, to the extent they have been derived from such annual financial statements is based solely on the report of such other auditors.

Independent Auditors' Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)

Certain of these subsidiaries and joint ventures are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's Management has converted the financial statements of such subsidiaries and joint ventures located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's Management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries and joint ventures located outside India is based on the report of other auditors and the conversion adjustments prepared by the Management of the Company and audited by us.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

5. In our opinion and to the best of our information and according to the explanations given to us and based on consideration of reports of other auditors on separate financial statements of the subsidiaries and joint ventures as aforesaid, these consolidated annual financial results:
- i) include the annual financial results of the following entities included in Annexure A;
 - ii) have been presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - iii) give a true and fair view of the net consolidated profit and other comprehensive income and other financial information for the year ended 31 March 2019.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration Number: 116231W/W-100024



Sriram Mahalingam

Partner

Membership Number: 049642

Place: Hyderabad

Date: 28 May 2019

Independent Auditors' Report on Annual Consolidated Financial Results of Aurobindo Pharma Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (continued)

Annexure A

List of subsidiaries and joint ventures

S.No.	Component Name	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary
9	Natrol LLC	USA	Subsidiary
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Aurobindo Pharma USA LLC (dissolved w.e.f. 31 March 2018, revived w.e.f. 06 June 2018)	USA	Subsidiary
14	Auro AR LLC	USA	Subsidiary
15	Auro Vaccines LLC	USA	Subsidiary
16	Auro Logistics LLC	USA	Subsidiary
17	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
18	Helix Healthcare B.V.	The Netherlands	Subsidiary
19	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
20	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
21	Novagen Pharma (Pty) Limited	South Africa	Joint venture
22	Auro Pharma Inc.	Canada	Subsidiary
23	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
24	Auro Healthcare (Nigeria) Limited (Liquidated w.e.f. 20 March 2019)	Nigeria	Subsidiary
25	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
26	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
27	Agile Pharma B.V.	The Netherlands	Subsidiary
28	Arrow Generiques SAS	France	Subsidiary
29	1980 Puren Pharma GmbH (formerly Actavis Management GmbH)	Germany	Subsidiary
30	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary
31	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Subsidiary
32	Aurobindo Pharma B.V. (formerly Actavis B.V.)	The Netherlands	Subsidiary
33	Aurex B.V. (formerly Pharmacin B.V.)	The Netherlands	Subsidiary
34	Aurobindo Pharma GmbH	Germany	Subsidiary
35	Aurobindo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceutica S.A w.e.f 01 April 2018)	Portugal	Subsidiary

Annexure A (continued)

List of subsidiaries and joint ventures (continued)

S.No.	Component Name	Country	Relationship
36	Laboratorios Aurobindo S.L.	Spain	Subsidiary
37	Aurobindo Pharma (Italia) S.r.l	Italy	Subsidiary
38	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
39	Aurovitas, Unipessoal LDA (Merged with Generis Farmaceutica S.A w.e.f 01 April 2018)	Portugal	Subsidiary
40	Pharmacin B.V. (formerly Aurex B.V.)	The Netherlands	Subsidiary
41	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
42	APL Swift Services (Malta) Limited	Malta	Subsidiary
43	Milpharm Limited	United Kingdom	Subsidiary
44	Aurovitas Pharma Polska	Poland	Subsidiary
45	Generis Farmaceutica S.A	Portugal	Subsidiary
46	Mer Medicamentos, Lda. (Merged with Generis Farmaceutica S.A w.e.f 01 April 2018)	Portugal	Subsidiary
47	Generis Phar, Unipessoal Lda.	Portugal	Subsidiary
48	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary
49	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
50	Hyacinths Pharma Private Limited	India	Subsidiary
51	Raidurgam Developers Limited (formerly Aurobindo Antibiotics Ltd)	India	Joint Venture
52	AuroZymes Limited	India	Subsidiary
53	Curepro Parenterals Limited	India	Subsidiary
54	Eugia Pharma Specialities Limited	India	Joint venture
55	Tergene Biotech Private Limited	India	Joint venture
56	Auro Pharma India Private Limited	India	Subsidiary
57	Aurovitas Pharma Ceska republika s.r.o	Czech Republic	Subsidiary
58	Aurovitas Pharma (Taizhou) Ltd	China	Subsidiary
59	Acrotech Biopharma LLC	USA	Subsidiary
60	Purple Bellflower (Pty) Ltd (w.e.f. 23 August 2018)	South Africa	Joint Venture
61	Auroscience (Pty) Ltd (w.e.f. 25 September 2018)	Australia	Subsidiary
62	Auro Science LLC (w.e.f 28 March 2019)	USA	Subsidiary
63	Apotex Nederland BV, NL (w.e.f. 8 February 2019)	The Netherlands	Subsidiary
64	APOTEX ESPANA SL (w.e.f. 8 February 2019)	Spain	Subsidiary
65	APOTEX CR spol.s.r.o (w.e.f. 8 February 2019)	Czech Republic	Subsidiary
66	Apotex SA/NV (w.e.f. 8 February 2019)	Belgium	Subsidiary
67	Apotex Polska Sp.z.o.o (w.e.f. 8 February 2019)	Poland	Subsidiary
68	Apotex Europe BV (w.e.f. 8 February 2019)	The Netherlands	Subsidiary
69	Sameko Farma B.V. (w.e.f. 8 February 2019)	The Netherlands	Subsidiary
70	Leidapharm B.V. (w.e.f. 8 February 2019)	The Netherlands	Subsidiary
71	Marel B.V. (w.e.f. 8 February 2019)	The Netherlands	Subsidiary
72	Pharma Dossier B.V. (w.e.f. 8 February 2019)	The Netherlands	Subsidiary
73	Aurobindo Pharma FZ LLC, Dubai (w.e.f 6 January 2019)	U.A.E.	Subsidiary
74	Curateq Biologics GmbH (w.e.f. 20 March 2019)	Switzerland	Subsidiary

64

Annexure-1**PROFILE OF DIRECTORS****Mrs. Savita Mahajan**

Mrs. Savita Mahajan is holding a degree in Economics and MBA from IIM Ahmedabad. She was associated with the ISB for 14 years, since its inception in 2001, and was responsible for building its second campus at Mohali, Punjab, as its CEO. She holds a degree in Economics from Delhi University and did her MBA from the Indian Institute of Management, Ahmedabad, in 1981. Since then, she worked in several Indian organizations, including Maruti Udyog Limited, Bharat Technologies, Karvy Consultants, and Intergraph India, in diverse industry sectors, including automobiles, engineering, financial services and software. Her professional interests include Strategic Management, Institutional Values, Leadership and Organizational Change. She has also carried out consulting and training assignments for corporations and development organizations, including GE Capital, the Planning Commission, the World Bank, and the Tibetan Government in exile of His Holiness, the Dalai Lama. Mrs. Savita Mahajan was featured in Business Today's 2013 list of "30 Most Powerful Women" in Indian Business.

Dr.(Mrs)Avnit Bimal Singh

Dr. (Mrs.) Avnit Bimal Singh, holds an M.B.B.S. degree and is a Post Graduate in obstetrics & gynecology. She is a medical practitioner and a senior obstetrician/gynecologist based at Hyderabad.

Mr.P.Sarath Chandra Reddy

Mr.P.Sarath Chandra Reddy is a graduate of Business Administration. He is a second generation entrepreneur and belongs to the promoter group. He has gained experience in general management, procurement, clinical trials, trading in chemicals and information technology, logistics and project executions.



NEWS RELEASE

28th May 2019, Hyderabad, India

Aurobindo Pharma Ltd Q4 FY18-19 and FY18-19 Financial Results

Consolidated Financial Results – FY18-19 & Q4FY18-19

Amount in INR Cr	FY18-19	FY17-18	% Chg
Revenue from Operations	19,563.6	16,499.8	18.6
EBITDA before Forex and Other income	3,951.9	3,788.5	4.3
EBITDA %	20.2%	23.0%	
PBT before Forex and Exceptional Items	3,237.0	3,254.8	-0.5
Net Profit after JV share, minority interest	2,364.7	2,423.2	-2.4

Amount in INR Cr	Q4 FY18-19	Q4 FY17-18	% Chg	Q3 FY18-19	% Chg
Revenue from Operations	5,292.2	4,049.1	30.7	5,269.7	0.4
EBITDA before Forex and Other income	1,060.3	804.0	31.9	1,086.4	-2.4
EBITDA %	20.0%	19.9%		20.6%	
PBT before Forex and Exceptional Items	855.9	666.5	28.4	889.0	-3.7
Net Profit after JV share, minority interest	585.4	528.5	10.8	712.2	-17.8

Key Highlights of FY18-19 consolidated Financials

- Revenue from Operations at INR 19,563.6 Cr, witnessed a strong growth of 18.6% over the last year
 - US formulation sales increased by 21.3% YoY to INR 9,030.7 Cr
 - Europe formulation sales at INR 4,960.2 Cr, an increase of 13.9% over the last year
 - Growth Markets posted a strong growth of 33.1% YoY to INR 1,193.7 Cr
 - ARV sales up by 15.8% YoY to INR 972.5 Cr
 - API sales witnessed a healthy growth of 14.9% YoY to INR 3,403.0 Cr
- EBITDA before Forex and Other income at INR 3,951.9 Cr, an increase of 4.3% YoY; EBITDA margin for the year was at 20.2%
- Net Profit after JV share, minority interest at INR 2,364.7 Cr as against INR 2,423.2 Cr in the corresponding previous period.
- Basic & Diluted EPS is INR 40.36 per share.
- Research & Development (R&D) spend at INR 871.6 Cr, 4.5% of revenues
- Received final approval for 48 ANDAs and tentative approval for 6 ANDA from USFDA

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Key Highlights of Q4FY19 consolidated financials

- Revenue from Operations at INR 5,292.2 Cr, witnessed a strong growth of 30.7% over corresponding previous period
 - US formulation sales of INR 2,481.1 Cr vs INR 1,738.8 Cr in Q4FY18, registering a robust growth of 42.7% YoY
 - Europe formulation sales at INR 1,311.8 Cr, an increase of 13.9% against Q4 last year
 - Growth Markets posted a strong growth of 37.9% YoY to INR 289.1 Cr
 - ARV sales at INR 291.5 Cr vs. INR 148.6 Cr, an increase of 96.2% over corresponding previous period
 - API sales witnessed a healthy growth of 14.6% YoY to INR 916.8 Cr
- EBITDA before Forex and Other income at INR 1,060.3 Cr vs INR 804.0 Cr in Q4 last year, grew by 31.9%; EBITDA margin for the quarter was at 20.0%
- Net Profit after JV share, minority interest at INR 585.4 Cr as against INR 528.5 Cr in the corresponding previous period, witnessing a growth of 10.8% YoY.
- Basic & Diluted EPS is INR 9.99 per share.
- Research & Development (R&D) spend at INR 231.3 Cr, 4.4% of revenues
- Received final approval for 8 ANDAs from USFDA

Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said: *"We ended the year with a strong quarter as Formulation and API businesses witnessed a growth of 35% YoY and 15% YoY. We have successfully completed the acquisitions of Apotex's businesses in five European countries and branded Oncology injectables from Spectrum Pharmaceuticals, USA during the quarter. Our near-term priorities are to integrate the acquired businesses, improve the efficiencies and achieve synergies. Steady progress on our differentiated pipeline during the year coupled with the recent acquisitions will drive the future growth."*

Operational Performance (Consolidated):

(Amt in INR Cr)	FY18-19	FY17-19	% Chg
Formulations			
USA	9,030.7	7,442.1	21.3
Europe	4,960.2	4,354.4	13.9
Growth Markets	1,193.7	897.1	33.1
ARV	972.5	839.6	15.8
Total Formulations	16,157.0	13,533.2	19.4
Active Pharmaceuticals Ingredients (API)			
Betalactum	2,145.9	1,992.3	7.7
Non Betalactum	1,257.1	969.9	29.6
Total API	3,403.0	2,962.2	14.9
Consolidated Gross Sales	19,560.1	16,495.4	18.6
Dossier Income	3.5	4.4	
Revenue from operations	19,563.6	16,499.8	18.6

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059



Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com



Amount in INR Cr	Q4 FY18-19	Q4 FY17-18	% Chg	Q3 FY18-19	% Chg
Formulations					
USA	2,481.1	1,738.8	42.7	2,433.2	2.0
Europe	1,311.8	1,151.6	13.9	1,292.8	1.5
Growth Markets	289.1	209.6	37.9	340.5	-15.1
ARV	291.5	148.6	96.2	281.3	3.6
Total Formulations	4,373.6	3,248.6	34.6	4,347.8	0.6
Active Pharmaceuticals Ingredients (API)					
Betalactum	583.0	532.7	9.4	557.7	4.6
Non Betalactum	333.7	266.9	25.0	364.1	-8.3
Total API	916.8	799.6	14.6	921.7	-0.5
Consolidated Sales	5,290.3	4,048.3	30.7	5,269.6	0.4
Dossier Income	1.9	0.8		0.1	
Revenue from Operations	5,292.2	4,049.1	30.7	5,269.7	0.4

Consolidated Revenue breakup - Geography & segment wise

FY19



Q4FY19



AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Formulations

Formulation revenue for the year recorded a growth of 19.4% YoY to INR 16,157.0 Cr and accounted for 82.6% of total revenues. For the quarter, Formulation revenue registered a growth of 34.6% to INR 4,373.6 Cr

US Formulations

- In FY19, US revenue increased by 21.3% YoY to INR 9,030.7 crore and accounting 46.2% of consolidated revenue. On constant currency basis, revenue grew by 11.8% YoY
- US revenue for Q4FY19 witnessed a growth of 42.7% YoY to INR 2,481.1 crore, accounting 46.9% of consolidated revenue. On constant currency basis, revenue grew by 30.4% YoY
- Filed 22 ANDAs with USFDA including 6 injectables in Q4FY19 and 63 ANDAs including 21 injectables in FY19
- Received final approval for 8 ANDAs in Q4FY19 and 48 ANDAs including 8 injectables in FY19
- As on 31st Mar 2019, on a cumulative basis, the company filed 541 ANDAs with USFDA and received approval for 403 ANDAs including 26 tentative* approvals
- The company has launched 15 products including 4 injectables during the quarter. For the year, the company launched 50 products including 12 injectable products
- During the quarter, Acrotech Biopharma LLC., a wholly owned subsidiary of Aurobindo Pharma USA Inc., which in turn is a wholly owned subsidiary of the Company has successfully completed the acquisition of 7 branded oncology injectable products from Spectrum Pharmaceuticals Inc.

**Tentative approvals include 9 ANDAs approved under PEPFAR.*

EU Formulations

- EU revenue in FY19 posted a growth of 13.9% YoY to INR 4,960.2 crore, accounting 25.4% of consolidated revenue. In Euro terms, revenue grew by 6.6% YoY
- EU revenue in Q4FY19 witnessed a robust growth of 13.9% YoY to INR 1,311.8 crore, accounting 24.8% of consolidated revenue. In Euro terms, revenue grew by 12.7% YoY
- During the quarter, the company has successfully completed the acquisition of Apotex's commercial operations and certain supporting infrastructure in five European countries

ARV Formulations

- ARV business revenue for FY19 was at INR 972.5 Cr compared to INR 839.6 Cr, an increase of 15.8% YoY and accounted for 5.0% of revenue
- ARV business revenue for 4QFY19 was at INR 291.5 Cr Vs. INR 148.6 Cr in Q4FY18, witnessed a robust growth of 96.2% and accounted for 5.5% of revenue

Growth Markets Formulations

- Revenue from Growth markets formulations in FY19 posted a strong growth of 33.1% YoY to INR 1,193.7 Cr and accounted for 6.1% of revenue
- Revenue from Growth markets formulations in Q4FY19 up by 37.9% YoY to INR 289.1 Cr and accounted for 5.5% of revenue

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

API business

- In FY19, API business posted a growth of 14.9% YoY to INR 3,403 Cr and contributed ~17.4% to the consolidated revenues
- In Q4FY19, API business registered a growth of 14.6% to INR 916.8 Cr
- The company filed 6 DMFs with USFDA during the quarter and 15 DMFs in FY19.

Global Regulatory Filings:

Filings	Q4 FY18-19	Cumulative Filings as on 31 st Mar 2019
ANDAs (including filings made from Aurobindo USA)	22	541
DMFs (including filings made from AuroNext and AuroPeptide)	6	242
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada)	30	3,583
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	25	2,905

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

USFDA approvals received in Q4 FY18-19:**Final Approvals**

1	Letrozole (gFemara) Tab 2.5mg	Anti-Neoplastic
2	Eletriptan Hydrobromide (gRelpax) Tab 20mg and 40mg	Anti-Migraine
3	Dofetilide (gTikosyn) Cap 0.125 mg, 0.25 mg and 0.5 mg	Anti-Arrhythmic
4	Aripiprazole (gAbilify) Oral Solution 1 mg/mL	CNS
5	Tadalafil (gAdcirca) Tab 20 mg	CVS
6	Diphenhydramine Hydrochloride and Ibuprofen (gAdvil PM) Cap (OTC) 25 mg / 200 mg	Anti-Histamine
7	Tadalafil (gCialis) Tab 2.5 mg, 5 mg, 10 mg and 20 mg	CVS
8	Doxepin Hydrochloride (gSinequan) Cap USP	Anti-Depressant

Earnings call details

The company will host an earnings call at 8.30 AM IST on May 29th 2019, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below

Primary Number: +91 22 6280 1437 / +91 22 7115 8825

Local Access Number: +91 70456 71221 (Available all over India)

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:

Krishna Kiran

Investor Relations

Phone: 040-66725401 / 66725000

Mobile: +91 98486 67906

Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2019					
Particulars	Quarter ended			Year ended	
	31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from operations					
(a) Net sales/ income from operations (refer note 4)	5,20,198	5,17,526	3,98,863	19,22,592	16,23,287
(b) Other operating income	9,022	9,441	6,046	33,763	26,697
Total revenue from operations	5,29,220	5,26,967	4,04,909	19,56,355	16,49,984
2 Other income					
(a) Foreign exchange gain (net)	-	5,045	-	-	-
(b) Others	3,227	1,340	4,383	11,566	10,198
Total other income	3,227	6,385	4,383	11,566	10,198
Total income (1+2)	5,32,447	5,33,352	4,09,292	19,67,921	16,60,182
3 Expenses					
(a) Cost of materials consumed	1,99,129	1,92,256	1,42,779	7,44,499	5,62,937
(b) Purchase of stock-in-trade	51,222	55,184	46,673	1,94,320	1,60,588
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(13,088)	(8,452)	(22,505)	(67,555)	(48,251)
(d) Employee benefits expense	71,346	64,980	58,127	2,58,487	2,13,084
(e) Finance costs	5,008	4,765	2,472	16,266	7,771
(f) Foreign exchange loss (net)	284	-	1,592	6,028	1,676
(g) Depreciation and amortisation expense	18,662	16,312	15,663	66,795	55,797
(h) Other expenses	1,14,580	1,14,361	99,432	4,31,410	3,82,774
Total expenses	4,47,143	4,39,406	3,44,233	16,50,250	13,36,376
4 Profit before share of profit of joint ventures, exceptional item (1+2-3)	85,304	93,946	65,059	3,17,671	3,23,806
5 Share of profit/(loss) of joint ventures, net of tax	(52)	257	56	270	314
6 Profit before exceptional items and tax (4+5)	85,252	94,203	65,115	3,17,941	3,24,120
7 Exceptional items (refer note 6)	3,618	2,504	-	8,806	-
8 Profit before tax (6-7)	81,634	91,699	65,115	3,09,135	3,24,120
9 Tax expense					
Current tax	18,998	21,365	4,222	71,207	71,230
Tax credit - Minimum Alternate Tax (MAT)	1,658	(2,551)	(3,450)	(5,100)	(4,332)
Deferred tax	2,456	1,664	11,467	6,578	14,930
Total tax expense	23,112	20,478	12,239	72,685	81,828
10 Net profit for the period/year after tax and before non-controlling interest (8-9)	58,522	71,221	52,876	2,36,450	2,42,292
11 Share of profit/(loss) attributable to non-controlling interest	(16)	(1)	25	(23)	(26)
12 Net profit after taxes attributable to owners of the Parent Company (10-11)	58,538	71,222	52,851	2,36,473	2,42,318
13 Other Comprehensive Income/(Loss)					
A) Items that will not be reclassified subsequently to profit or loss:					
i) Re-measurement of defined employee benefit liability	(122)	(49)	283	(261)	(367)
ii) Income-tax relating to items that will not be reclassified to profit or loss	57	14	(87)	107	130
B) Items that will be reclassified subsequently to profit or loss:					
i) Exchange differences on translating the financial statements of foreign operations	(5,637)	(17,309)	10,184	(266)	15,191
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-
Total other comprehensive income/(loss)	(5,702)	(17,344)	10,380	(420)	14,954
14 Total Comprehensive income for the period/year (12+13)	52,836	53,878	63,231	2,36,053	2,57,272
15 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859
16 Other equity				13,83,219	11,62,183
17 Earnings per equity share (face value Re. 1 per share)					
(a) Basic (in Rs.)	9.99	12.15	9.02	40.36	41.36
(b) Diluted (in Rs.)	9.99	12.15	9.02	40.36	41.36

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059

Regd. Off.: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com

www.aurobindo.com

NOTES:

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
 - 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
 - 3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 28 May 2019. The statutory auditors have carried out audit of the above results for year ended 31 March 2019. An unqualified report has been issued by them thereon.
 - 4 Post implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenues from operations is disclosed net of GST. Revenue from operations for the quarter and year ended 31 March 2019, quarter ended 31 March 2018 and quarter ended 31 December 2018 are reported net of GST. The year ended 31 March 2018 include excise duty upto 30 June 2017.
 - 5 Effective 1 April 2018, the Group has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
 - 6 Exceptional items for the current period/year represents acquisition related costs.
 - 7 The Group operates in only one segment viz., 'Pharmaceutical Products'.
 - 8 During the quarter:
 - i) Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA, Inc. acquired certain identified business (Portfolio of oncology injectable business) from Spectrum Pharmaceuticals Inc. w.e.f. 1 March 2019.
 - ii) The following companies are acquired w.e.f. 8 February 2019:
 - (a) Aurovitas Pharma Polska, a wholly owned subsidiary of Agile Pharma B.V. acquired Apotex Polska S.p. z.o.o., Poland
 - (b) Aurovitas Pharma Ceska Republica s.r.o, a wholly owned subsidiary of Agile Pharma B.V. acquired APOTEX (CR) Spol. s.r.o. Czech Republic.
 - (c) Aurovitas Spain S.A. a wholly owned subsidiary of Agile Pharma B.V. acquired APOTEX ESPANA SL, Spain.
 - (d) Aurobindo Pharma B.V. a wholly owned subsidiary of Agile Pharma B.V. acquired Apotex N.V, Belgium, Apotex Europe B.V., The Netherlands and Apotex Nederland B.V., The Netherlands, which has wholly owned step down subsidiaries Sameko Farma B.V, The Netherlands, Leidapharm B.V, The Netherlands, Marel B.V, The Netherlands and Pharma Dossier B.V, The Netherlands.
 - iii) The following Companies are incorporated :
 - a) Curateq Biologics GmbH, Switzerland was incorporated as whollyowned subsidiary of Helix Healthcare B.V, The Netherland w.e.f. 20 March 2019.
 - b) Aurobindo Pharma FZ-LLC, Dubai was incorporated as wholly owned subsidiary of Helix Healthcare B.V, The Netherland w.e.f. 1 January 2019
 - c) Auro Science LLC, U.S.A was incorporated as wholly owned subsidiary of Aurobindo Pharma USA, Inc., w.e.f.28 March 2019.
- The consolidated financial results for the current quarter and year ended 31 March 2019 include the results of operations of the above entities from their respective dates of acquisition or incorporation. The corresponding figures for the previous periods are not comparable.
- 9 The figures of the quarter ended 31 March 2019 and 31 March 2018 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2019 and 31 March 2018 respectively and the unaudited published year to date figures upto 31 December 2018 and 31 December 2017 respectively, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended 31 December 2018 and 31 December 2017 have been subjected to the limited review by the statutory auditors.
 - 10 Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date : 28 May 2019

www.aurobindo.com

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Consolidated Balance Sheet

(Rs. In lakhs)

Sl. No.	PARTICULARS	As at 31.03.2019	As at 31.03.2018
		(Audited)	(Audited)
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	5,69,365	4,73,656
	Capital work-in-progress	1,34,194	1,39,954
	Goodwill	83,251	81,654
	Other intangible assets	1,94,869	96,757
	Intangible assets under development	32,652	18,350
	Financial assets		
	Investments	36,020	31,152
	Loans	646	544
	Trade receivables	119	-
	Other financial assets	8,938	8,684
	Deferred tax assets (net)	18,329	15,880
	Non-current tax assets (net)	13,811	8,259
	Other non-current assets	16,792	17,398
	Total non-current assets	11,08,986	8,92,288
2	Current assets		
	Inventories	7,24,560	5,85,842
	Financial assets		
	Investments	2	2
	Trade receivables	3,41,378	3,08,020
	Cash and cash equivalents	1,88,607	1,21,590
	Bank balances other than cash and cash equivalents	7,111	4,635
	Loans	1,026	866
	Other financial assets	1,36,346	79,420
	Current tax assets (net)	3,456	6,455
	Other current assets	1,33,965	1,10,987
	Total current assets	15,36,451	12,17,817
	TOTAL ASSETS	26,45,437	21,10,105
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,859
	Other equity	13,83,219	11,62,183
	Non-controlling interest	159	182
	Total equity	13,89,237	11,68,224
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	17,995	45,120
	Provisions	4,654	5,586
	Deferred tax liabilities (net)	28,131	23,528
	Other non-current liabilities	1,130	1,057
	Total non-current liabilities	51,910	75,291
3	Current liabilities		
	Financial liabilities		
	Borrowings	6,57,321	4,03,134
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises and	3,361	3,083
	total outstanding dues of creditors other than micro enterprises and small enterprises	2,64,352	2,34,207
	Other financial liabilities	1,66,146	1,50,452
	Other current liabilities	88,395	46,291
	Provisions	18,088	19,728
	Current tax liabilities (net)	6,627	9,695
	Total current liabilities	12,04,290	8,66,590
	TOTAL EQUITY AND LIABILITIES	26,45,437	21,10,105

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com